Gracell Biotechnologies Inc. American Depositary Shares
GRCL
GRCL was delisted on the 21st of February, 2024.
36 hedge funds and large institutions have $321M invested in Gracell Biotechnologies Inc. American Depositary Shares in 2021 Q1 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
30.86% more ownership
Funds ownership: 0% → 30.86% (+31%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$186M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$62.4M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$35.9M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$31.7M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$28.1M |
Top Sellers
GRCL Hedge Fund Activity: Q1 2021 in Review
36 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Gracell Biotechnologies Inc. American Depositary Shares (GRCL) for Q1 2021, worth a combined $321M.
Buyers outnumbered sellers: 36 funds opened new GRCL positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $186M.
- 36 institutional investors held Gracell Biotechnologies Inc. American Depositary Shares (GRCL) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $321M of Gracell Biotechnologies Inc. American Depositary Shares stock for Q1 2021.
- 36 funds opened new Gracell Biotechnologies Inc. American Depositary Shares positions in Q1 2021 and 0 closed out, a net change of +36 holders.
- The largest Gracell Biotechnologies Inc. American Depositary Shares buyer in Q1 2021 was OrbiMed, an estimated $186M added.
Based on aggregated 13F filings for Q1 2021.